Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

Cathy Tie, who launched her first biotech in SF's IndieBio, now leads Manhattan Genomics in controversial push to edit human ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Health Secretary Robert F. Kennedy Jr. called the treatment 'a powerful glimpse into the future of personalized medicine' ...

VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo!

Kimberly-Clark is buying Tylenol maker Kenvue in a $48.7B deal, creating a massive consumer health goods company And I do ...

The apparel industry accounts for 10% of greenhouse gas emissions. Biotechs are working on reengineering natural products to make more sustainable textiles, which are gaining traction.

As flu season approaches and public health officials roll out their annual push for vaccination, Allen Institute scientists ...

Xenotransplantation is the fusion energy of medicine. As the well-worn joke goes, it is the future—and always will be. But ...